PARP1 and asthenia: Analysis of patients in the overall population showed that, compared with the control arms, PARP inhibitors were associated with a decreased risk of asthenia (RR, 0.34; 95%CI, 0.14–0.82) but increased risk of neutropenia (RR, 1.14; 95%CI, 1.01–1.29).